Abstract:Background: Over the past decade, there has been an exponential accumulation of digital patient data through molecular profiling and digitization of pathology slides. However, integrating this to advance diagnostics and cancer patient care remains a significant challenge. By integrating information from diverse modalities to capture aspects of the tumor microenvironment (TME) and immune landscape, we aim to improve patient stratification for immunotherapy. Methods: We collected data from baseline biopsies from patients with palpable melanoma stage III (n=195) who received neoadjuvant immunotherapy followed by surgical resection of largest lymph node metastasis. The different modalities included clinical information, whole-genome sequencing (WGS), RNAseq, laboratory tests of blood, haematoxylin and eosin (H&E) images, and PDL1 immunohistochemistry (IHC) images. Cell detection and classification models were trained to identify tumor-infiltrating lymphocytes and tumor cells on H&E whole-slide images (WSI), deriving spatial features to quantitatively describe the tumor-immune interaction. Various biomarkers, including tumor mutational burden, BRAF status, expression of inflammatory gene signatures, systemic neutrophil-to-lymphocyte ratio, and tumor-lymphocyte spatial measures, were collectively integrated using machine learning models (random forest, elastic-net regularized logistic regression, CatBoost, support vector machine (SVM), and an ensemble classifier combined from the other models) within a 5x5-fold nested cross-validation scheme to predict pathologic response. Results: Pathologic response to immunotherapy is associated with multi-omics biomarkers which were integrated using machine learning. The ensemble approach showed that when all modalities were combined a higher AUC (AUC=0.69, 0.61-0.77) could be achieved than for the clinical modality alone. RNA plus clinical emerged as the most predictive standalone modality with an AUC of 0.62 (0.50-0.75). The overall highest AUC was achieved using a SVM (AUC=0.72, 0.66-0.82). Conclusions: Immunotherapy efficacy depends on diverse tumor microenvironment components, which were comprehensively assessed through data integration. A multi-omic predictive model holds promise for refining personalized and effective immunotherapy strategies. Citation Format: Lindsay V. Leek, Vanessa Botha, Vipul A. Baxi, Jonas Teuwen, Hugo M. Horlings, Scott D. Chasalow, Joris van de Haar, Lodewyk F. Wessels, Auditi DebRoy, Emile E. Voest. Integrative multi-omic machine learning model predicts neoadjuvant immunotherapy response using molecular data and deep learning-derived features from digital pathology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4951.

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

Prediction of Immunotherapy Response by Integrating Immune Infiltration and Neoantigen Presentation Score in Late-Stage Melanoma.

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Integrated Modeling to Implicate Evolving Neoantigen-T Cell Interplays and Immunotherapy Efficacy in Tumors

Prediction of immunotherapy responsiveness in melanoma through single-cell sequencing-based characterization of the tumor immune microenvironment

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

A Novel Integrated Approach to Predicting Cancer Immunotherapy Efficacy

Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.

P853 Single cell transcriptome analysis identifies unique features in circulating CD8+ T cells that can predict immunotherapy response in melanoma patients

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Abstract 4951: Integrative multi-omic machine learning model predicts neoadjuvant immunotherapy response using molecular data and deep learning-derived features from digital pathology

A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies

Identifying Biomarkers Associated with Immunotherapy Response in Melanoma by Multi-Omics Analysis.

Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators

Robust Immunoscore Model to Predict the Response to Anti-Pd1 Therapy in Melanoma.

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients